Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation

This study has been completed.

Sponsor:

Novo Nordisk A/S

ClinicalTrials.gov Identifier:

NCT01562158

First Posted: March 23, 2012

Last Update Posted: January 11, 2017

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.